Steg PG, Bhatt DL, Simon T, et al. - In a randomized, double-blind trial, experts allotted individuals who were 50 years of age or older and who had stable coronary artery disease and T2DM to receive either ticagrelor plus aspirin or placebo plus aspirin in order to determine whether adding ticagrelor to aspirin enhanced outcomes in such population. A total of 19,220 individuals underwent randomization. In both the groups, the incidence of an exploratory composite outcome of inevitable harm (death from any cause, myocardial infarction, stroke, fatal bleeding, or intracranial hemorrhage) was comparable. Those who received ticagrelor plus aspirin had a lower prevalence of ischemic cardiovascular events although a greater incidence of major bleeding in comparison with those who received placebo plus aspirin, among individuals with stable coronary artery disease and diabetes with no history of myocardial infarction or stroke.